Shallu Kutlehria

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/824072/publications.pdf

Version: 2024-02-01

95 papers	3,185 citations	126907 33 h-index	182427 51 g-index
98 all docs	98 docs citations	98 times ranked	4626 citing authors

#	Article	IF	Citations
1	Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45Î±, integrin-Î±5, -Î²5, -Î²1, and autophagy. Drug Delivery and Translational Research, 2022, , 1.	5.8	6
2	Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. International Immunopharmacology, 2022, 107, 108693.	3.8	18
3	Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts. Pharmaceutics, 2022, 14, 1156.	4.5	4
4	Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 172-184.	4.3	9
5	Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. Materials Science and Engineering C, 2021, 119, 111460.	7.3	14
6	Sustained release dosage form of noscapine HCl using hot melt extrusion (HME) technique: formulation and pharmacokinetics. Drug Delivery and Translational Research, 2021, 11, 1156-1165.	5.8	3
7	Role of In Vitro Models for Development of Ophthalmic Delivery Systems. Critical Reviews in Therapeutic Drug Carrier Systems, 2021, 38, 1-31.	2.2	9
8	Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells. Journal of Pharmaceutical Analysis, 2021, 11, 799-807.	5.3	5
9	Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 4215-4228.	1.1	7
10	Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. International Journal of Pharmaceutics, 2021, 607, 120943.	5.2	27
11	Polysaccharide hydrogel based 3D printed tumor models for chemotherapeutic drug screening. Scientific Reports, 2021, 11, 372.	3.3	45
12	Nasal delivery of nanotherapeutics for CNS diseases: challenges and opportunities. Nanomedicine, 2021, 16, 2651-2655.	3.3	5
13	Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface. International Journal of Molecular Sciences, 2020, 21, 8890.	4.1	8
14	Highâ€throughput <scp>3D</scp> bioprinting of corneal stromal equivalents. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2020, 108, 2981-2994.	3.4	41
15	The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Nonâ€“Small Cell Lung Cancer. Journal of Pharmaceutical Sciences, 2020, 109, 1867-1882.	3.3	16
16	Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts. Toxicology and Applied Pharmacology, 2020, 401, 115112.	2.8	18
17	Epstein-Barr Virus LMP1 Promotes Syntenin-1- and Hrs-Induced Extracellular Vesicle Formation for Its Own Secretion To Increase Cell Proliferation and Migration. MBio, 2020, 11, .	4.1	43
18	Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products. International Journal of Pharmaceutics, 2020, 586, 119560.	5.2	168

#	Article	IF	Citations
19	Current Development of Oral Taxane Formulations: A Review. Critical Reviews in Therapeutic Drug Carrier Systems, 2020, 37, 205-227.	2.2	6
20	Withaferin A reverses bile duct ligationâ€induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2/Snail1, vimentin, and NFÎºB signaling. BioFactors, 2019, 45, 959-974.	5.4	14
21	Combination of UVB Absorbing Titanium Dioxide and Quercetin Nanogel for Skin Cancer Chemoprevention. AAPS PharmSciTech, 2019, 20, 240.	3.3	17
22	Whole-Eye Perfusion Model for Screening of the Ocular Formulations via Confocal Laser Scanning Microscopy. AAPS PharmSciTech, 2019, 20, 307.	3.3	5
23	Withaferin A ameliorates renal injury due to its potent effect on inflammatory signaling. BioFactors, 2019, 45, 750-762.	5.4	20
24	Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 31-43.	3.3	12
25	Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. AAPS PharmSciTech, 2019, 20, 135.	3.3	18
26	Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength. Drug Delivery and Translational Research, 2019, 9, 816-827.	5.8	37
27	Characterization and printability of Sodium alginate -Gelatin hydrogel for bioprinting NSCLC co-culture. Scientific Reports, 2019, 9, 19914.	3.3	106
28	Actinomycin D and Telmisartan Combination Targets Lung Cancer Stem Cells Through the Wnt/Beta Catenin Pathway. Scientific Reports, 2019, 9, 18177.	3.3	21
29	Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation. Pharmaceutical Research, 2018, 35, 117.	3.5	20
30	Cholecalciferol-PEG ConjugateÂBased Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer. AAPS PharmSciTech, 2018, 19, 792-802.	3.3	26
31	Drug delivery strategies for chemoprevention of <scp>UVB</scp>â€induced skin cancer: A review. Photodermatology Photoimmunology and Photomedicine, 2018, 34, 60-68.	1.5	21
32	Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells. AAPS PharmSciTech, 2018, 19, 3287-3297.	3.3	25
33	A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget, 2018, 9, 29680-29697.	1.8	11
34	Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. Journal of Controlled Release, 2017, 246, 120-132.	9.9	61
35	Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). Colloids and Surfaces B: Biointerfaces, 2017, 153, 208-219.	5.0	49
36	Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer. Pharmaceutical Research, 2017, 34, 2371-2384.	3.5	27

#	Article	IF	Citations
37	Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. Scientific Reports, 2017, 7, 15824.	3.3	31
38	Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. PLoS ONE, 2017, 12, e0185116.	2.5	24
39	CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget, 2016, 7, 73370-73388.	1.8	11
40	Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems. Critical Reviews in Therapeutic Drug Carrier Systems, 2016, 33, 309-361.	2.2	72
41	Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Experimental Cell Research, 2016, 346, 65-73.	2.6	29
42	Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine, 2016, 11, 1377-1392.	3.3	40
43	NR4A1 Antagonists Inhibit Î²1-Integrin-Dependent Breast Cancer Cell Migration. Molecular and Cellular Biology, 2016, 36, 1383-1394.	2.3	49
44	Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer. Molecular Pharmaceutics, 2016, 13, 2049-2058.	4.6	39
45	Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 168-179.	4.3	35
46	Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation. Drug Delivery and Translational Research, 2016, 6, 526-539.	5.8	7
47	Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids and Surfaces B: Biointerfaces, 2016, 143, 156-167.	5.0	29
48	Percutaneous delivery ofÎ±-melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis. Journal of Drug Targeting, 2016, 24, 537-547.	4.4	12
49	Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer. Drug Delivery, 2016, 23, 1232-1241.	5.7	49
50	AlgiMatrixâ„¢-Based 3D Cell Culture System as an In Vitro Tumor Model: An Important Tool in Cancer Research. Methods in Molecular Biology, 2016, 1379, 117-128.	0.9	18
51	Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharmaceutical Research, 2016, 33, 137-154.	3.5	32
52	Nuclear receptor 4A (NR4A) family â€“ orphans no more. Journal of Steroid Biochemistry and Molecular Biology, 2016, 157, 48-60.	2.5	149
53	Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine. PLoS ONE, 2016, 11, e0146804.	2.5	12
54	Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS). Oncotarget, 2016, 7, 31257-31269.	1.8	23

#	Article	IF	Citations
55	Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. Journal of Pharmaceutical Sciences, 2015, 104, 4417-4426.	3.3	53
56	Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation. Molecular Pharmaceutics, 2015, 12, 1105-1120.	4.6	60
57	Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity. Pharmaceutical Research, 2015, 32, 2292-2300.	3.5	10
58	Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity. Journal of Controlled Release, 2015, 213, 18-26.	9.9	11
59	Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. International Journal of Pharmaceutics, 2015, 489, 106-116.	5.2	47
60	Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocrine-Related Cancer, 2015, 22, 831-840.	3.1	51
61	Nanomiemgel - A Novel Drug Delivery System for Topical Application - In Vitro and In Vivo Evaluation. PLoS ONE, 2014, 9, e115952.	2.5	58
62	Approaches to Improve the Oral Bioavailability and Effects of Novel Anticancer Drugs Berberine and Betulinic Acid. PLoS ONE, 2014, 9, e89919.	2.5	113
63	CARP-1 Functional Mimetics Are a Novel Class of Small Molecule Inhibitors of Malignant Pleural Mesothelioma Cells. PLoS ONE, 2014, 9, e89146.	2.5	17
64	Mechanisms of Neuroblastoma Cell Growth Inhibition by CARP-1 Functional Mimetics. PLoS ONE, 2014, 9, e102567.	2.5	12
65	Opening Up the Optical Imaging Window Using Nano-Luciferin. Pharmaceutical Research, 2014, 31, 3073-3084.	3.5	9
66	Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, e1053-e1063.	3.3	19
67	Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. Journal of Controlled Release, 2014, 184, 67-78.	9.9	46
68	31P solid-state NMR based monitoring of permeation of cell penetrating peptides into skin. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 190-199.	4.3	14
69	Investigation of Follicular and Non-follicular Pathways for Polyarginine and Oleic Acid-Modified Nanoparticles. Pharmaceutical Research, 2013, 30, 1037-1049.	3.5	51
70	Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. Journal of Controlled Release, 2013, 172, 86-95.	9.9	66
71	Efficacy of Aerosolized Celecoxib Encapsulated Nanostructured Lipid Carrier in Non-small Cell Lung Cancer in Combination with Docetaxel. Pharmaceutical Research, 2013, 30, 1435-1446.	3.5	55
72	Design, Synthesis of Novel Lipids as Chemical Permeation Enhancers and Development of Nanoparticle System for Transdermal Drug Delivery. PLoS ONE, 2013, 8, e82581.	2.5	35

#	Article	IF	Citations
73	AlgiMatrixâ„¢ Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies. PLoS ONE, 2013, 8, e53708.	2.5	189
74	Dermal Microdialysis Technique to Evaluate the Trafficking of Surface-Modified Lipid Nanoparticles upon Topical Application. Pharmaceutical Research, 2012, 29, 2587-2600.	3.5	42
75	Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer, 2011, 71, 271-282.	2.0	106
76	Encapsulation, Stability and In-vitro Release Characteristics of Liposomal Formulations of Colchicine. Journal of Pharmacy and Pharmacology, 2011, 49, 491-495.	2.4	22
77	Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer. PLoS ONE, 2011, 6, e17733.	2.5	93
78	Long-circulating monensin nanoparticles for the potentiation of immunotoxin and anticancer drugs. Journal of Pharmacy and Pharmacology, 2010, 53, 617-627.	2.4	28
79	Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-lineâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 899-907.	2.4	30
80	Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin. Journal of Pharmacy and Pharmacology, 2010, 55, 819-825.	2.4	9
81	Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. Journal of Pharmacy and Pharmacology, 2010, 56, 19-25.	2.4	16
82	Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. Toxicology Letters, 2009, 185, 168-174.	0.8	11
83	In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDermâ„¢ (EPI-200) cultured human skin and hairless rats. Toxicology Letters, 2006, 167, 85-94.	0.8	27
84	Stability and degradation profiles of Spantide II in aqueous solutions. European Journal of Pharmaceutical Sciences, 2006, 27, 158-166.	4.0	8
85	Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. International Journal of Cancer, 2006, 118, 396-404.	5.1	51
86	In vitro and in vivo evaluation of topical formulations of Spantide II. AAPS PharmSciTech, 2005, 6, E565-E572.	3.3	53
87	Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: Characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension. AAPS PharmSciTech, 2005, 6, E573-E585.	3.3	43
88	Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist: Spantide II. Pharmaceutical Research, 2004, 21, 108-113.	3.5	23
89	Comparison of the Transdermal Absorption of Nimesulide from Three Commercially Available Gel Formulations. Drug Development and Industrial Pharmacy, 2002, 28, 297-304.	2.0	8
90	Effect of jet fuels on the skin morphology and irritation in hairless rats. Toxicology, 2002, 175, 35-47.	4.2	35

#	Article	IF	Citations
91	Percutaneous permeation and skin irritation of JP-8+100 jet fuel in a porcine model. Toxicology Letters, 2001, 119, 133-142.	0.8	17
92	Stealth monensin immunoliposomes as potentiator of immunotoxins in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2001, 52, 13-20.	4.3	17
93	Encapsulation, Stability, and In Vitro Release Characteristics of Liposomal Formulations of Stavudine (D4T). Drug Delivery, 1999, 6, 31-37.	5.7	10
94	Trends in Drug Targeting for Cancer Treatment. Drug Delivery, 1996, 3, 289-304.	5.7	13
95	Long circulating liposomes of 2â€²,3â€²-dideoxyinosine: Formulation and stability. Drug Delivery, 1996, 3, 279-287.	5.7	3